Project Grant R41AI191930
Award Date 9/5/25
Completion Date 8/31/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $593,860 Project Grant through the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Massachusetts (UMass) for the development of new polymer-phage conjugate nanoparticles to treat antibiotic-resistant wound biofilm infections. The 5-year project, which began on June 6, 2025, seeks to create phage-polymer nanoparticles that can effectively penetrate and eradicate biofilm infections...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $184,375 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Florida International University (FIU). The grant aims to optimize and evaluate a novel antimicrobial peptide, A4-X7, for aerosolized pulmonary delivery to treat antibiotic-resistant bacterial respiratory infections, including those caused by ESKAPE pathogens. The proposed research will prepare,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...
- This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing while...
- This $481,250 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant will fund the development of new antimicrobial small molecule compounds that recruit the immune system to target bacteria. Key activities include the biochemical, biophysical, and cell biology characterization of these chimeric molecules formed by joining bacterial binding agents with...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $158,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Temple University to conduct an exploratory study on a new pH-responsive, ionizable hybrid nanocarrier for enhancing drug delivery to bacterial biofilms. The goal is to develop a nanocarrier design that can effectively deliver a range of therapeutic agents to biofilms, which are the main cause of chronic wound infections...
- This Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research by Fimbrion Therapeutics Inc. to develop small molecule glycoside inhibitors targeting the LecB lectin protein in Pseudomonas aeruginosa (PA) bacteria. The goal is to create novel therapeutics to disrupt PA biofilm formation and enhance the efficacy of antibiotics in treating PA infections,...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 SBIR Phase 1 project grant to Biotherapeutics, Inc. under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of the project is to develop a novel, host-targeted, antibiotic-sparing oral therapeutic for concomitant Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD). The specific aims are to: 1) Compare the efficacy of the novel oral immunoregulatory therapeutic...